USE OF GENETICALLY MODIFIED PATHOGENIC MEASLES VIRUS WITH IMPROVED APOPTOTIC PROPERTIES (MV-DELTAC VIRUS) IN CANCER THERAPY Russian patent published in 2019 - IPC C12N7/00 C12N5/00 A61K35/768 

FIELD: medicine.

SUBSTANCE: invention relates to genetic engineering. Described is the use of pathogenic measles virus (MV) from a live attenuated measles virus (MV) strain in which a gene encoding a viral accessory protein C (MV-deltaC) is knocked out, in treating an aggressive malignant tumour or aggressive cancer when administered to an individual diagnosed with such a malignant tumour or cancer. Described is a method of producing vaccine plasmacytoid dendritic cells (PDC) for treating an aggressive malignant tumour or aggressive cancer in an individual diagnosed with such a malignant tumour or cancer, involving the following stages: in vitro infection of a malignant tumour or cancer cells pre-selected from said individual with pathogenic measles virus (MV), in which a gene encoding a viral accessory protein C (MV-deltaC) is knocked out to obtain a cell lysate; bringing PDC into contact with cell lysate to obtain vaccine PDC; extraction of loaded PDC.

EFFECT: invention extends the range of measles treatment agents.

15 cl, 24 dwg, 14 ex